Drugs / Zepbound
Zepbound cost
tirzepatide · Eli Lilly. Official self-pay prices by strength, what Medicare and savings offers cover, and the cost-related parts of the FDA label.
The short version
- Single-dose vial: lowest listed self-pay price $299 per fill (2.5 mg); highest regular price $449 per fill.[1]
- For 7.5, 10, 12.5, 15 mg, the listed price applies to on-time refills; a refill more than 45 days after the last one costs $499 or $699.[1]
- This listing gives a price for a quantity of 1 and does not say how many days it covers. We are confirming the supply length with Eli Lilly's own pages.[1]
- KwikPen (multi-dose): lowest listed self-pay price $299 per fill (2.5 mg); highest regular price $449 per fill.[2]
- For 7.5, 10, 12.5, 15 mg, the listed price applies to on-time refills; a refill more than 45 days after the last one costs $499 or $699.[2]
- This listing gives a price for a quantity of 1 and does not say how many days it covers. We are confirming the supply length with Eli Lilly's own pages.[2]
- Medicare GLP-1 Bridge: only the KwikPen (multi-dose) is covered; single-dose vials are not. People who qualify pay $50 for a one-month supply.[3][4]
Zepbound Single-dose vial: price by strength
Sold through LillyDirect (Eli Lilly self-pay). About this channel.
| Strength | Price per fill | Conditions in the official listing | List price (WAC) |
|---|---|---|---|
| 2.5 mg | $299 | — | $1,087 |
| 5 mg | $399 | — | $1,087 |
| 7.5 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $499. | $1,087 |
| 10 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $1,087 |
| 12.5 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $1,087 |
| 15 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $1,087 |
“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
Full offer terms: www.lilly.com/lillydirect/medicines/zepbound/self-pay-terms-conditions
Zepbound KwikPen (multi-dose): price by strength
Sold through LillyDirect (Eli Lilly self-pay). About this channel.
| Strength | Price per fill | Conditions in the official listing | List price (WAC) |
|---|---|---|---|
| 2.5 mg | $299 | — | $499 |
| 5 mg | $399 | — | $499 |
| 7.5 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $499. | $499 |
| 10 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $699 |
| 12.5 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $699 |
| 15 mg | $449 | On-time refills. If a refill is more than 45 days after the last one: $699. | $699 |
“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
Full offer terms: www.lilly.com/lillydirect/medicines/zepbound/self-pay-terms-conditions
Price history
Tracking began Oct 17, 2026. A new row appears only after a person has checked a change against the official page. All changes · Download CSV
| Checked | Form | Strengths | Lowest | Highest regular |
|---|---|---|---|---|
| 2026-10-17 | Single-dose vial | 2.5, 5, 7.5, 10, 12.5, 15 mg | $299 | $449 |
| 2026-10-17 | KwikPen (multi-dose) | 2.5, 5, 7.5, 10, 12.5, 15 mg | $299 | $449 |
From the FDA label
Word for word from the label on DailyMed: what the drug is approved for, the strengths and pack sizes (how many doses come in one carton or bottle), and the label's dose schedule.
FDA-approved uses · label 1
ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:
- to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
- to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Limitations of Use
ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.
Dosage forms and strengths · label 3
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
| Single-dose Pen or Vial |
| 2.5 mg/0.5 mL |
| 5 mg/0.5 mL |
| 7.5 mg/0.5 mL |
| 10 mg/0.5 mL |
| 12.5 mg/0.5 mL |
| 15 mg/0.5 mL |
| Multi-dose Vial (4 doses per vial) | ||
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg/0.6 mL | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg/0.6 mL | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg/0.6 mL | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg/0.6 mL | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg/0.6 mL | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg/0.6 mL | 60 mg/2.4 mL | 25 mg/mL |
| Single-Patient-Use KwikPen (4 doses per KwikPen) | ||
| Dose per Injection | Total Strength per Total Volume | Strength per mL |
| 2.5 mg | 10 mg/2.4 mL | 4.17 mg/mL |
| 5 mg | 20 mg/2.4 mL | 8.33 mg/mL |
| 7.5 mg | 30 mg/2.4 mL | 12.5 mg/mL |
| 10 mg | 40 mg/2.4 mL | 16.7 mg/mL |
| 12.5 mg | 50 mg/2.4 mL | 20.8 mg/mL |
| 15 mg | 60 mg/2.4 mL | 25 mg/mL |
Dose schedule in the label · label 2.1
- The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks.
- The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.
- Follow the dosage escalation below for all indications to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].
- After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose [see Dosage and Administration (2.2)].
- Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.
Dose schedule in the label · label 2.2
Recommended Maintenance Dosage
Weight Reduction and Long-Term Maintenance
The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.
OSA
The recommended maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.
Maximum Recommended Dosage
The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.
How it is supplied (pack sizes) · label 16
16.1 How Supplied
ZEPBOUND (tirzepatide) is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, 4 single-dose vials, 1 multi-dose vial, or 1 single-patient-use KwikPen as follows:
| Single-Dose Vial and Prefilled Pen | |||
| Strength | 4 pack Single-dose Pen NDC | 1 pack Single-dose Vial NDC | 4 pack Single-dose Vial NDC |
| 2.5 mg/0.5 mL | 0002-2506-80 | 0002-0152-01 | 0002-0152-04 |
| 5 mg/0.5 mL | 0002-2495-80 | 0002-0243-01 | 0002-0243-04 |
| 7.5 mg/0.5 mL | 0002-2484-80 | 0002-1214-01 | 0002-1214-04 |
| 10 mg/0.5 mL | 0002-2471-80 | 0002-1340-01 | 0002-1340-04 |
| 12.5 mg/0.5 mL | 0002-2460-80 | 0002-1423-01 | 0002-1423-04 |
| 15 mg/0.5 mL | 0002-2457-80 | 0002-2002-01 | 0002-2002-04 |
| Multi-Dose Vial | ||
| Doses per Vial | Strength | 1 pack Multi-Dose Vial NDC |
| 4 doses of 2.5 mg/0.6 mL | 10 mg/2.4 mL (4.17 mg/mL) | 0002-6052-11 |
| 4 doses of 5 mg/0.6 mL | 20 mg/2.4 mL (8.33 mg/mL) | 0002-6103-11 |
| 4 doses of 7.5 mg/0.6 mL | 30 mg/2.4 mL (12.5 mg/mL) | 0002-6210-11 |
| 4 doses of 10 mg/0.6 mL | 40 mg/2.4 mL (16.7 mg/mL) | 0002-6304-11 |
| 4 doses of 12.5 mg/0.6 mL | 50 mg/2.4 mL (20.8 mg/mL) | 0002-6523-11 |
| 4 doses of 15 mg/0.6 mL | 60 mg/2.4 mL (25 mg/mL) | 0002-6612-11 |
| Single-Patient-Use KwikPen (with four weekly doses) | ||
| Doses per KwikPen | Strength | 1 pack Single-Patient-Use KwikPen NDC |
| 4 doses of 2.5 mg | 10 mg/2.4 mL (4.17 mg/mL) | 0002-3566-11 |
| 4 doses of 5 mg | 20 mg/2.4 mL (8.33 mg/mL) | 0002-3555-11 |
| 4 doses of 7.5 mg | 30 mg/2.4 mL (12.5 mg/mL) | 0002-3544-11 |
| 4 doses of 10 mg | 40 mg/2.4 mL (16.7 mg/mL) | 0002-3533-11 |
| 4 doses of 12.5 mg | 50 mg/2.4 mL (20.8 mg/mL) | 0002-3522-11 |
| 4 doses of 15 mg | 60 mg/2.4 mL (25 mg/mL) | 0002-3511-11 |
Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.
Official sources for this page
“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
TrumpRx.gov: Zepbound Single-dose vial listing · as of Oct 17, 2026“*Eligibility required, terms and conditions apply. Review full terms and conditions.”
TrumpRx.gov: Zepbound KwikPen (multi-dose) listing · as of Oct 17, 2026“Starting July 1, 2026, Medicare covers these GLP-1 drugs: Foundayo® (tablet) Wegovy® (injection or tablet) Zepbound® (KwikPen® only. The program doesn’t cover single-dose Zepbound® vials or pens).”
Medicare.gov: Weight loss drugs · as of Oct 17, 2026“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
Medicare.gov: Weight loss drugs · as of Oct 17, 2026